Neftaly Heart Failure Management Guidelines
Evidence-Based Care for Improved Cardiac Outcomes
Heart failure (HF) is a complex clinical syndrome resulting from structural or functional impairment of ventricular filling or ejection of blood. At Neftaly, our heart failure management guidelines are designed to align with international best practices while addressing local healthcare realities. Our goal is to provide a standardized, patient-centered approach to diagnosing, treating, and monitoring heart failure effectively.
1. Diagnosis and Initial Assessment
Early and accurate diagnosis is critical to improving outcomes. Neftaly recommends:
✔ Clinical Evaluation
- Assessment of signs and symptoms (e.g., dyspnea, fatigue, edema, orthopnea)
- Detailed patient history including risk factors (e.g., hypertension, diabetes, coronary artery disease)
✔ Diagnostic Tools
- Echocardiogram: To assess ejection fraction (HFrEF, HFpEF, HFmrEF)
- BNP/NT-proBNP Testing: For diagnostic support and monitoring
- ECG and Chest X-ray: To identify underlying structural abnormalities
- Laboratory Testing: Including renal function, electrolytes, thyroid function, and iron studies
2. Classification of Heart Failure
- HFrEF (Heart Failure with reduced Ejection Fraction): EF ≤ 40%
- HFpEF (Heart Failure with preserved Ejection Fraction): EF ≥ 50%
- HFmrEF (Mildly reduced EF): EF 41–49%
Treatment approaches differ based on classification and underlying etiology.
3. Pharmacologic Management
Neftaly guidelines emphasize evidence-based medication use to reduce mortality and hospitalizations:
For HFrEF:
- ACE Inhibitors / ARBs / ARNIs – For reducing symptoms and mortality
- Beta-Blockers – Carvedilol, bisoprolol, or metoprolol succinate
- Mineralocorticoid Receptor Antagonists (MRAs) – E.g., spironolactone
- SGLT2 Inhibitors – Dapagliflozin or empagliflozin
- Loop Diuretics – For fluid overload symptom relief
- Ivabradine – For select patients with persistent tachycardia
For HFpEF:
- Focus on symptom relief, blood pressure control, and management of comorbidities (e.g., diabetes, AF)
4. Non-Pharmacologic Management
- Lifestyle Modifications: Low-sodium diet, fluid restriction (as needed), weight monitoring, physical activity
- Patient Education: On symptom recognition, medication adherence, and when to seek care
- Cardiac Rehabilitation: Especially post-discharge or after acute decompensation
- Vaccinations: Annual flu and pneumococcal vaccines
5. Device and Advanced Therapies
- Implantable Cardioverter Defibrillators (ICD) for patients with HFrEF and reduced EF despite optimal therapy
- Cardiac Resynchronization Therapy (CRT) for select patients with dyssynchrony
- Referral for Advanced Therapies (LVAD, transplant) in end-stage heart failure
6. Follow-Up and Monitoring
- Regular clinical reviews to monitor symptoms, weight, vitals, and medication effectiveness
- Laboratory testing for kidney function and electrolytes, especially after initiating or adjusting medications
- Monitoring for adherence, depression, and psychosocial support needs
7. Palliative and End-of-Life Care
Neftaly emphasizes integrating palliative care early in advanced heart failure to manage symptoms and ensure patient comfort and dignity. Discussions on care preferences and advance directives are essential.
Implementation in Clinical Practice
Neftaly supports healthcare providers through:
- Training and Workshops
- Clinical Decision Support Tools
- Care Pathways and Referral Protocols
- Community-Based Management Models for low-resource settings
Neftaly’s Commitment
We aim to reduce the burden of heart failure by delivering consistent, high-quality care through structured guidelines, multidisciplinary collaboration, and patient empowerment.